Cargando…
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
Chronic kidney disease (CKD) is associated with very high mortality rates, mainly of cardiovascular origin. The retention of phosphate (P) and increased fibroblast growth factor-23 levels are common, even at early stages of CKD, due to disturbances in normal P homeostasis. Later, hyperphosphatemia a...
Autores principales: | Lloret, MªJesús, Ruiz-García, César, DaSilva, Iara, Furlano, Mónica, Barreiro, Yaima, Ballarín, José, Bover, Jordi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826937/ https://www.ncbi.nlm.nih.gov/pubmed/24235818 http://dx.doi.org/10.2147/PPA.S31694 |
Ejemplares similares
-
The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012) -
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009) -
Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011) -
Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009) -
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis
por: Zhao, Lijuan, et al.
Publicado: (2021)